cariboubio.com (CRBU): חוב להון עצמי

The success of Caribou Biosciences (CRBU) depends on the trial results of CRISPR drugs, while its liquidity cushion remains sufficient. This price action chart on GURU.Markets shows that the total debt-to-equity ratio is 0.26. The company's revenues will be driven by the market launch of universal lymphoma treatments. Risks are mitigated through the development of therapies for oncology and autoimmune pathologies.

The total debt-to-equity ratio determines the extent of a company's reliance on borrowed funds relative to its own equity. By analyzing the current leverage ratio (total debt to equity), an investor assesses the risk of insolvency in a rising rate environment. This metric compares total liabilities to the net asset value, revealing the level of debt burden. Low leverage is critically important for Caribou Biosciences (CRBU), as it ensures financial stability during the development of high-precision CRISPR platforms for cancer therapy.